Industry News

Biotechnology Industry News

GSK has walked away from a $2.2…

July 9th, 2026|FierceBiotech|

GSK has walked away from a $2.2 billion biobucks neurodegenerative disease pact with Alector that has seen both “next generation” drugs involved flunk clinical trials.

For a biotech, your intellectual…

July 8th, 2026|FierceBiotech|

For a biotech, your intellectual property is your most prized asset. But a new era of increased global competition means that strong patents, longer stealth periods and even some misdirection can be required to ensure

The FDA has paused a controversial…

July 8th, 2026|FierceBiotech|

The FDA has paused a controversial policy of releasing letters describing its rationale for rejecting drugs, Fierce Biotech has learned, following a citizen’s petition from an unnamed pharma company in April.

Insurance coverage losses caused…

July 8th, 2026|FierceBiotech|

Insurance coverage losses caused by the Trump administration's tax and spend law could make it harder for biotechs to secure funding and recruit patients for trials, experts have told Fierce.

Prime Medicine has come out ahead…

July 8th, 2026|FierceBiotech|

Prime Medicine has come out ahead in its patent dispute with fellow gene-editing biotech Beam Therapeutics, after a panel of adjudicators ruled that the company did not violate its agreement with Beam and can continue

Satellos Bioscience has shared…

July 8th, 2026|FierceBiotech|

Satellos Bioscience has shared evidence that its Duchenne muscular dystrophy drug candidate is active in adults, leading analysts to predict the molecule “could re-imagine the ... therapeutic landscape” if the biotech replicates the data in

Precision immunology company…

July 8th, 2026|FierceBiotech|

Precision immunology company Scipher Medicine will absorb Chemomab Therapeutics after having identified the Israeli biotech’s liver disease drug as the ideal fit for its own expertise.

AstraZeneca is paying Sino…

July 8th, 2026|FierceBiotech|

AstraZeneca is paying Sino Biopharmaceutical $200 million upfront for ex-China rights to a late-phase challenger to Merck & Co.’s chronic obstructive pulmonary disease drug Ohtuvayre.

Biocytogen and Whitehawk…

July 7th, 2026|FierceBiotech|

Biocytogen and Whitehawk Therapeutics are joining forces to develop bispecific antibody-drug conjugates using Biocytogen's discovery platform.

Phase 3 trials of Kailera…

July 7th, 2026|FierceBiotech|

Phase 3 trials of Kailera Therapeutics’ oral GLP-1 prospect have hit their primary endpoints, positioning the biotech’s partner Hengrui Pharma to seek approval in obesity and diabetes in China.

As U.S. lawmakers continue to…

July 7th, 2026|FierceBiotech|

As U.S. lawmakers continue to scrutinize the consequences of China’s expanding role in biotech innovation, industry insiders have been left debating how they can navigate this shifting landscape—or even whether biotechs should abandon China altogether.

Novartis is pushing deeper into…

July 6th, 2026|FierceBiotech|

Novartis is pushing deeper into antibody-drug conjugate development, paying $1.1 billion upfront to buy Myricx Bio for a pipeline based on a novel payload.

A month after Genentech confirmed…

July 5th, 2026|FierceBiotech|

A month after Genentech confirmed the restructuring of its early development group, the Roche subsidiary has now disclosed that this has formed part of a round of 103 layoffs.

AstraZeneca has added another…

July 3rd, 2026|FierceBiotech|

AstraZeneca has added another piece to its sprawling interface with CSPC Pharmaceutical, paying the Chinese biotech $30 million upfront to jointly discover and develop two kidney disease drug candidates.